Explore the latest clinical research, biomarkers, and therapeutic advances in diabetes and chronic kidney disease (CKD). This section highlights emerging evidence on early detection, cardiometabolic risk management, and innovative treatment approaches including SGLT2 inhibitors, metformin safety, and microbiome-related interventions. Stay updated with global trends, clinical guidelines, and preventive strategies aimed at improving kidney health and patient outcomes.
Prediabetes affects nearly one-third of U.S. adults and is increasingly implicated in early chronic kidney disease (CKD). Evidence links prediabetes with albuminuria, glomerular hyperfiltration, mild renal impairment, and elevated cardiovascular risk. Observational cohorts indicate an association with progression of proteinuria, though its independent role in advanced CKD is inconsistent. Proposed mechanisms include insulin resistance, low-grade hyperglycemia, altered tubuloglomerular feedback via sodium–glucose cotransporter-2 activity, inflammation, and endothelial dysfunction. Heterogeneous diagnostic thresholds across guidelines complicate risk stratification, and emerging biomarkers require further validation. Early detection with guideline-directed lifestyle and pharmacological interventions may mitigate CKD progression and cardiovascular outcomes, informing population-level screening and prevention strategies.
Read MoreDiabetic kidney disease (DKD) is a major complication of diabetes, characterized by albuminuria, progressive renal dysfunction, and increased cardiovascular risk. Chronic hyperglycemia drives its development, yet early detection remains challenging. Urinary biomarkers are increasingly investigated as tools for early diagnosis, risk stratification, and monitoring of disease progression. Albumin remains the established marker of early glomerular injury, while emerging proteins such as kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin reflect tubular damage. Metabolomic, genetic, and epigenetic signatures further enhance understanding of DKD pathophysiology and individual susceptibility. Integration of validated urinary biomarkers into clinical practice may enable earlier intervention, personalized therapy, and improved outcomes in DKD.
Read MoreChronic kidney disease (CKD) and diabetes mellitus are interconnected global health challenges, with diabetes driving CKD development in up to 40% of patients with type 2 diabetes. The rising prevalence of diabetes, intensified after the COVID-19 pandemic, necessitates early prevention, systematic screening, and integrated care. CKD is projected to become a leading cause of mortality by 2040 and develops through metabolic, vascular, and inflammatory mechanisms influenced by multiple risk factors. Management focuses on glycemic and blood pressure control, routine albuminuria and eGFR screening, renoprotective therapies (ACE inhibitors/ARBs, SGLT2 inhibitors, GLP-1 receptor agonists), and lifestyle interventions. Pharmacists play a key role in monitoring, education, adherence support, and early detection, reinforcing a multidisciplinary, prevention-oriented approach to slow CKD progression and improve outcomes.
Read MoreThe American Diabetes Association (ADA) 2026 Standards of Care represent a significant shift from a glucose-centric model toward a comprehensive cardio metabolic risk framework. Rather than focusing primarily on A1C reduction, the updated guidance recognizes cardiovascular disease, chronic kidney disease, and metabolic dysfunction as interconnected risks requiring integrated management. The 2026 standards emphasize patient-centered care, prioritizing lifestyle modification, preventive strategies, and pharmacotherapies with proven cardio protective and renoprotective benefits. Notably, SGLT2 inhibitors and GLP-1 receptor agonists are recommended not only for glycemic control but also for reducing heart failure events and slowing CKD progression, reflecting robust evidence from major clinical trials.
Read MoreUsing Global Burden of Disease 2021 data, the burden, trends, and projections of early-onset type 2 diabetes and diabetes-related chronic kidney disease among individuals aged 15–39 years were evaluated. The analysis showed steadily increasing disability-adjusted life years and age-standardized rates for early-onset type 2 diabetes, a modest rise in diabetes-related CKD disability burden, and declining age-standardized rates for CKD, with high body mass index accounting for over half of the burden for both conditions and marked variation across sociodemographic strata. Joint analysis of diabetes and its renal complication, supported by advanced trend and forecasting methods, provides a coherent picture of disease trajectories in young adults and identifies obesity and glycaemic control as key targets for prevention and health-system planning.
Read MoreChronic kidney disease affects up to 40% of individuals with diabetes, and non-diabetic kidney disease (NDKD) is common in this population. In a retrospective analysis of 115 diabetic patients who underwent native renal biopsy (2010–2024), diabetic nephropathy (DN) was identified in 43.5%, while vasculitis, membranous nephropathy, and amyloidosis were the most frequent NDKD diagnoses. Patients with DN were younger, had longer diabetes duration, higher HbA1c levels, more frequent insulin use, diabetic retinopathy, and nephrotic syndrome. Younger age, insulin therapy, and diabetic retinopathy were the strongest predictors of DN. These findings underscore the high prevalence of NDKD and support renal biopsy as the most accurate diagnostic approach in suspected atypical cases.
Read MoreSGLT2 inhibitors have transformed the management of diabetes, chronic kidney disease (CKD), and cardiovascular disease, but their role in advanced diabetic CKD has been less certain. Evidence from secondary analyses of major trials and recent studies in advanced CKD indicates that renal and cardiovascular benefits are maintained, without an increased risk of adverse outcomes such as acute kidney injury, diabetic ketoacidosis, infections, fractures, or amputations. Although use in dialysis patients remains investigational, preliminary data suggest potential benefits, including preservation of residual kidney function. Ongoing and future trials are expected to further define the pleiotropic effects and clinical utility of SGLT2 inhibitors in advanced CKD and kidney failure.
Read MoreMetformin remains first-line therapy for type 2 diabetes mellitus, though its use in chronic kidney disease (CKD) is limited by concerns about lactic acidosis. This updated meta-analysis of 12 observational studies assessed associations between metformin use and all-cause mortality, major cardiovascular events, end-stage renal disease (ESRD), and lactic acidosis in patients with CKD and diabetes. Metformin use was associated with reduced all-cause mortality (HR 0.76) and lower ESRD risk (HR 0.61), with no significant association with major cardiovascular events. A trend toward increased lactic acidosis risk was observed in CKD stage 4. Overall, despite very low-certainty evidence and heterogeneity, metformin appeared beneficial for survival and renal outcomes, highlighting the need for further studies addressing CKD stage and dose-specific effects.
Read MoreCardiovascular risk in type 2 diabetes is amplified by the presence of chronic kidney disease (CKD). As the urinary albumin-to-creatinine ratio exceeds 10 mg/g and estimated glomerular filtration rate declines below 75 mL/min/1.73 m², the risks of cardiovascular events and incident heart failure increase. In most patients with CKD, cardiovascular risk exceeds the risk of kidney failure, underscoring the importance of early CKD detection and targeted treatment to reduce the burden of cardiovascular disease and heart failure in type 2 diabetes.
Read MoreUsing Global Burden of Disease 2021 data from 204 countries, this study examined global trends in chronic kidney disease (CKD) due to type 1 diabetes, type 2 diabetes (T2DM), hypertension, and glomerulonephritis from 1990 to 2021, with projections to 2045. In 2021, CKD affected 673.7 million people, predominantly driven by T2DM and hypertension. Incidence rates for all etiologies continued to rise, while age-standardized prevalence declined for T1DM- and glomerulonephritis-related CKD. T2DM contributed the highest mortality and disability burden, with population growth and aging as key drivers, particularly in middle-SDI regions. Regional and socioeconomic disparities were pronounced, and projections indicate further increases in CKD due to T2DM and hypertension, highlighting the need for targeted public health interventions.
Read MoreSodium–glucose cotransporter-2 (SGLT2) inhibitors have transformed the management of kidney and cardiovascular disease beyond their original role as glucose-lowering agents for type 2 diabetes. Robust evidence demonstrates their ability to slow chronic kidney disease progression, reduce cardiovascular events, and lower hospitalization risk, leading to their inclusion in major clinical guidelines. However, real-world uptake remains suboptimal, and uncertainty persists regarding their effectiveness in populations underrepresented in earlier trials, particularly patients with very low estimated glomerular filtration rate or minimal albuminuria.
Read MoreIn this nationwide cohort of 1.44 million parous women in France, gestational diabetes mellitus (GDM) was associated with an increased risk of kidney disease. Over 10 years, women with prior GDM had higher risks of chronic kidney disease (CKD) and acute kidney injury (AKI), with the association stronger for CKD. Adjustment for postpartum hypertension and type 2 diabetes substantially attenuated these risks, particularly for AKI. Elevated kidney disease risk emerged within one year postpartum and was greatest among women with recurrent GDM, indicating an early and cumulative association between GDM and CKD.
Read MoreEarly kidney function decline is a common complication of type 2 diabetes mellitus (T2DM). In a retrospective cohort of 125 patients with baseline and 1-year follow-up eGFR measurements (2023–2024), mean eGFR decreased by 3.8 mL/min/1.73 m², with 7.2% experiencing a ≥30% decline. Decline was significantly greater in those with pre-existing CKD. Poor glycemic control (HbA1c >7.5%) and elevated blood pressure (>130/80 mmHg) were independently associated with larger eGFR reductions, while lower BMI predicted greater decline across CKD strata. Lipid target attainment showed minimal and inconsistent associations. Overall, suboptimal glycemic and blood pressure control were the strongest modifiable predictors of short-term renal decline, particularly in patients without established CKD.
Read MoreDiabetic acute kidney disease (AKD) is a high-risk transitional state between acute kidney injury and chronic kidney disease. Management is anchored in renin–angiotensin–aldosterone system inhibition, with expanding evidence for sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, which reduce AKD progression, heart failure, and mortality. Finerenone improves outcomes in established diabetic CKD, though its role in AKD remains unclear. Despite proven benefits, real-world uptake of these therapies is suboptimal due to clinical inertia, post-AKI safety concerns, and socioeconomic barriers. Timely, combined use of guideline-directed therapies and evaluation of emerging agents are essential to improve renal and cardiovascular outcomes in diabetic AKD.
Read More